We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
ICU Medical
ICUI
$3.94B
| $21.1M | 0.05% |
118,292
-5,609
| -5% | -$1.03M |
|
377
Cognex
CGNX
$10.1B
| $20.9M | 0.05% |
373,106
-123,331
| -25% | -$6.38M |
|
|
SIX
378
DELISTED
Six Flags Entertainment Corp.
SIX
| $20.8M | 0.05% |
800,120
+300,000
| +60% | +$7.76M |
|
379
Skywest
SKYW
$3.73B
| $20.7M | 0.05% |
508,209
-21,060
| -4% | -$626K |
|
380
Intuit
INTU
$90.6B
| $20.7M | 0.05% |
45,142
-11,021
| -20% | -$4.83M |
|
381
Elanco Animal Health
ELAN
$11.6B
| $20.5M | 0.05% |
2,039,987
+36,544
| +2% | +$339K |
|
382
Cooper Companies
COO
$10.3B
| $20.3M | 0.05% |
212,064
-38,144
| -15% | -$3.58M |
|
383
Fair Isaac
FICO
$21.6B
| $20.3M | 0.05% |
25,036
-1,122
| -4% | -$841K |
|
384
Privia Health
PRVA
$2.61B
| $20.2M | 0.05% |
773,363
+272,236
| +54% | +$7.19M |
|
385
Q2 Holdings
QTWO
$3.86B
| $20.2M | 0.05% |
653,268
-41,318
| -6% | -$1.08M |
|
386
Trade Desk
TTD
$7.03B
| $20M | 0.05% |
+258,938
| New | +$17.5M |
|
387
Archer Daniels Midland
ADM
$41.7B
| $20M | 0.05% |
264,281
+39,654
| +18% | +$3M |
|
388
WEC Energy
WEC
$34.3B
| $19.9M | 0.05% |
225,745
-32,398
| -13% | -$2.99M |
|
389
Brown & Brown
BRO
$22.1B
| $19.9M | 0.05% |
288,441
-17,847
| -6% | -$1.14M |
|
390
Vaxcyte
PCVX
$8.86B
| $19.8M | 0.05% |
396,434
+319,521
| +415% | +$15.1M |
|
|
NVO
391
Novo Nordisk
NVO
$192B
| $19.8M | 0.05% |
244,388
+26,076
| +12% | +$2.13M |
|
392
Warner Bros
WBD
$70.5B
| $19.8M | 0.05% |
1,576,288
+476,587
| +43% | +$6.18M |
|
393
Intapp
INTA
$2.85B
| $19.7M | 0.05% |
470,593
-30,832
| -6% | -$1.33M |
|
394
ASML
ASML
$605B
| $19.7M | 0.05% |
27,160
+2
| +0% | +$1.36K |
|
395
CarGurus
CARG
$3.07B
| $19.6M | 0.05% |
866,017
-1,816,801
| -68% | -$34.4M |
|
396
John Wiley & Sons Class A
WLY
$2.45B
| $19.5M | 0.05% |
574,434
-22,001
| -4% | -$801K |
|
397
Martin Marietta Materials
MLM
$36.2B
| $19.5M | 0.05% |
42,287
-1,952
| -4% | -$770K |
|
398
Parsons
PSN
$4.89B
| $19.3M | 0.05% |
401,513
-11,651
| -3% | -$531K |
|
399
Parker-Hannifin
PH
$120B
| $19.3M | 0.05% |
49,494
-22,540
| -31% | -$7.63M |
|
400
United Rentals
URI
$61.6B
| $19.3M | 0.05% |
43,252
-37,309
| -46% | -$13.8M |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.